Concepedia

Hongshan Li

HL

49

Publications

2.7K

Citations

28

H-Index

1998

Active since

Affiliations

Center for Drug Evaluation and Research(Current)

Shanghai University of Traditional Chinese Medicine

Shuguang Hospital

Ningbo No. 2 Hospital

United States Food and Drug Administration

Hongshan Li is an author at Center for Drug Evaluation and Research specializing in medicine, pharmacology, and health sciences.

ORCID

Top concepts

Publications per year

1998–2024

49

Publications

49

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond

Lee H. Pai-Scherf, Gideon M. Blumenthal, Hongshan Li et al. · The Oncologist · 2017 · 286 citations · Full text

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

Maitreyee Hazarika, Meredith K. Chuk, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 181 citations

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft

Chau-Ming Cheng, Stewart P. Johnson, Stephen T. Keir et al. · Molecular Cancer Therapeutics · 2005 · 172 citations

Molecular Characterization of the β-<i>N</i>-Acetylglucosaminidase of<i>Escherichia coli</i>and Its Role in Cell Wall Recycling

Qiaomei Cheng, Hongshan Li, Keith D. Merdek et al. · Journal of Bacteriology · 2000 · 166 citations · Full text

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Hongshan Li, Jingyu Yu, Chao Liu et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2017 · 135 citations

, , +8

Rows per page

1–5 of 49